Liver Infarction after Drug-Eluting Embolic Transarterial Chemoembolization for Hepatocellular Carcinoma in the Setting of a Large Portosystemic Shunt

Adverse events related to hepatic ischemia may occur after transarterial chemoembolization (TACE) and are noted more frequently in patients with portosystemic shunts. The presented case describes hepatic infarction after drug-eluting embolic (DEE) TACE in a patient with a large, presumably congenital portosystemic shunt. The authors will discuss risk factors for adverse outcomes after TACE in the setting of portosystemic shunts and present strategies to minimize such complications.

• References

• 1 Bruix J, Sherman M ; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (3) 1020-1022
• 2 Tarazov PG, Polysalov VN, Prozorovskij KV, Grishchenkova IV, Rozengauz EV. Ischemic complications of transcatheter arterial chemoembolization in liver malignancies. Acta Radiol 2000; 41 (2) 156-160
• 3 Fujiwara H, Kanazawa S, Hiraki T , et al. Hepatic infarction following abdominal interventional procedures. Acta Med Okayama 2004; 58 (2) 97-106
• 4 Raoul JL, Sangro B, Forner A , et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37 (3) 212-220
• 5 A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. N Engl J Med 1995; 332 (19) 1256-1261
• 6 Garwood ER, Fidelman N, Hoch SE, Kerlan Jr RK, Yao FY. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction. Liver Transpl 2013; 19 (2) 164-173
• 7 Hsin IF, Hsu CY, Huang HC , et al. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction. J Clin Gastroenterol 2011; 45 (6) 556-562
• 8 Boulin M, Adam H, Guiu B , et al. Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma. Dig Liver Dis 2014; 46 (4) 358-362
• 9 Bouvier A, Ozenne V, Aubé C , et al. Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. Eur Radiol 2011; 21 (8) 1719-1726
• 10 Jin B, Wang D, Lewandowski RJ , et al. Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma. AJR Am J Roentgenol 2011; 196 (4) 919-928
• 11 Tesdal IK, Wikström M, Flechtenmacher C, Filser T, Dueber C. Percutaneous treatment of hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. Cardiovasc Intervent Radiol 2006; 29 (5) 778-784
• 12 Kang JW, Kim JH, Ko GY, Gwon DI, Yoon HK, Sung KB. Transarterial chemoembolization for hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt. Acta Radiol 2012; 53 (5) 545-550
• 13 Wang Z, Zhang H, Zhao H , et al. Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Diagn Interv Radiol 2014; 20 (6) 487-491
• 14 Miura JT, Rilling WS, White SB , et al. Safety and efficacy of transarterial chemoembolization in patients with transjugular intrahepatic portosystemic shunts. HPB (Oxford) 2015; 17 (8) 707-712
• 15 Kohi MP, Fidelman N, Naeger DM, LaBerge JM, Gordon RL, Kerlan Jr RK. Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong?. J Vasc Interv Radiol 2013; 24 (1) 68-73
• 16 Gaba RC, Rim CM, Parvinian A. Re: Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong?. J Vasc Interv Radiol 2013; 24 (7) 1075-1076
• 17 Lammer J, Malagari K, Vogl T , et al; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33 (1) 41-52
• 18 van Malenstein H, Maleux G, Vandecaveye V , et al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 2011; 34 (7) 368-376
• 19 Gorodetski B, Chapiro J, Schernthaner R , et al. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol 2016;
• 20 Kuo YC, Kohi MP, Naeger DM , et al. Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol 2013; 36 (5) 1336-1343
• 21 Padia SA, Chewning RH, Kogut MJ , et al. Outcomes of Locoregional Tumor Therapy for Patients with Hepatocellular Carcinoma and Transjugular Intrahepatic Portosystemic Shunts. Cardiovasc Intervent Radiol 2015; 38 (4) 913-921
• 22 Park JK, Al-Tariq QZ, Zaw TM, Raman SS, Lu DS. Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma in Patients with Transjugular Intrahepatic Portosystemic Shunts. Cardiovasc Intervent Radiol 2015; 38 (5) 1211-1217
• 23 Donahue LA, Kulik L, Baker T , et al. Yttrium-90 radioembolization for the treatment of unresectable hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 2013; 24 (1) 74-80